Biomeditsina va amaliyot jurnali, 2022 №2
Maqola mavzusi
EFFICACY OF TREATMENT OF INTRAVESICAL CHEMOTHERAPY IN NONINVASIVE MUSCULAR BLADDER CANCER (214-224)
Mualliflar
Tillyashaykhova Rano, Dzhuraev Mirzhalol, Tillyashaykhov Mirzagolib, Adylkhodzhaev Askar, Rakhimov Nodir
Muassasa
Tashkent city branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology Samarkand State Medical Institute
Annotatsiya
ANNOTATION Bladder cancer is the second most common tumor among all neoplasms of the genitourinary tract in the world. The most common is urothelial (transitional cell) RMP, which accounts for up to 90- 95% of all bladder tumors. In most cases, treatment of superficial bladder cancer begins with transurethral resection (TUR). Depending on the characteristics of the group of patients and the duration of follow-up, up to 80% of surface tumors recur and 2-50% progress to a muscle-invasive tumor. Intravesical therapy is currently widely used to prevent recurrence and, less often, to treat superficial bladder cancer. Along with the surgical removal of the tumor, it is necessary to carry out treatment aimed at preventing relapses and preventing progression. For this purpose, intravesical chemotherapy (VPHT) or immunotherapy is used. The most effective drugs in the near-surface RMP are adriamycin (doxorubicin), pharmarubicin (epirubicin). Thus, VPHT is widely used in the treatment of patients with superficial RMP.
Kalit so'zlar
Key words: bladder cancer, intravesical chemotherapy, transurethral resection.
Adabiyotlar
1. Kaasinen E., Wijkstrom H., Malmistrom P.-U. et al. Alternating Mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a Nordic study. Eur Urol 2018; 43: 637-45. 2. Herr H. The value of second transurethral resection in evaluating patients with bladder tumors. Urology 2018; 162: 74-6. 3. Klan R., Loy V., Huland H. Residual tumor discovered in routine second transurethralresec- tion in patients with T1 transitional cell carcinoma of the bladder. Urology 2017; 146: 316-8. 4. Oosterlinck W., Lobel B., Jakse G. el al. Gudelines on bladder cancer. EurUrol2012; 41(2): 105-12. 5. Матвеев Б.П. Химиотерапия поверхностного рака мочевого пузыря. В кн. Клиническая онкоурология. Подред.проф. Б.П. Матвеева. М., 2019; с. 260-70. 6. Sylvester R., Van der Meijden A., Witjes J.A., Kurth K. Bacilus Calmette-Guerin versus chemotherapy in the intravesical treatment of carcinoma in situ: a metaanalysis of the published results of randomized clinical trials. Eur Urol Suppl 2019; 4(3): 219. 7. Lamm D.L. Diagnosis and treatment of bladder cancer. Anti-Cancer Drugs 2020; 3(1): 39-47. 8. Kurth K., Tunn U., Ay R. et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European organization for research and treatment of cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 2020; 158(2): 378-84. 9. Pawinski A., Boulfioux C., Sylvester R. et al. Meta-analysis of EORTC/MRC random mixed clinical trials for prophylactic treatment of Ta. T1 bladder cancer. J Urol 2018; 155: 492A. 10. Tolley D.A., Parmar M.K.B., Grigor K.M., Lallemand G. and the Medical research council superficial bladder cancer working party. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J Urol 2019; 155(4): 1233-8. 11. Solsona E., Iborra I., Ricos J.V. et al. Effectiveness of a single immediate Mitomycin C instillation in patients with low risk superficial bladder cancer: short and long term followup. J Urol 2019; 161(4): 1120-3. 12. European Association of Urology Guidelines. 2006; p. 1-17. 13. Koga H., Kuroiwa K., Yaqmagushi A. et al. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder. J Urol 2017; 171(1): 153-7. 14. Secine H., Fukui I., Yamada T. et al. Intravesical Mitomycin C and Doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. JUrol 2019; 151(1): 27- 30. 15. Туйчиев А.П. Файзиев И. И. Урозов Н.Э. Рахимов Н.М Факторы Прогноза Выживаемости У Пациентов С Мышечно-Инвазивной Уротелиальной Карциномой Мочевого Пузыря После Радикальной Цистэктомии// Central asian journal of medical and natural sciences Volume: 02 Issue: 05 | Sep-Oct 2021. Стр 254-261 . 1. 16. Ali-El-Dein B., Nabeen A., Ismail E-H., Ghoneim M. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: arandomized prospective study. J Urol 2017; 162(2): 339-42. 16. Rintala E., Jauhiainen K., Kaasinen E., et al. Alternating Mitomycin C and Bacillus Calmette- Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. J Urol 2017; 156(1): 56-60. 17. Rakhimov Nodir Makhammatkulovich, Yigitaliyev Alisher Baxodirovich Determining the optimal prognostic factor for non-invasive bladder cancer// Polish Science Journal (ISSUE 12(33), 2020) - Warsaw: Sp. z o. o. "iScience", 2020. P. 99-104 19. Witjes J.A., Caris C.T.M., Mungan N.A. et al. Results of randomized phase III trial of sequential intravesical therapy with Mitomycin C and Bacillus Calmette-Guerin versus Mitomycin C alone patients with superficial bladder cancer. J Urol 2018; 160(5): 1668-72. 21. Koga H., Hasui Y., Fujimoto N., et al. A randomized controlled trial of prophylactic intravesical instillation chemotherapy in combination with the oral administration of a Lactobacillus Casei preparation versus intravesical instillation chemotherapy alone for recurrence after a transurethral resection of superficial bladder cancer. J Urol 2018; 173(4): 249. 22. Tillashayhov M N. Rakhimov N.M. Boyko E.V. Khashimov R.A. Results of Transurethral Resection of En-Blos Muscular Non-Invasive Bladder Cancer at the Republican Specialised CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES Volume: 02 Issue: 04 | Jul-Aug 2021. Стр 43-46 23. Mirzagaleb Nigmatovich Tillashayhov, Elena Vladimirovna Boyko, Ravshan Abdurasulovich Khashimov, Nodir Mahammatkulovich Rakhimov Transurethral Resection Of En-Bloс Muscularis Non - Invasive Bladder Cancer// The American Journal of Medical Sciences and Pharmaceutical Research (ISSN – 2689-1026) Published: June 28, 2021. 24. Mitsumori K., Tsuchiya N., Habuchi T. et al. Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral re4section. BJU Int 2019; 94: 317-21. 25. Kuroda M., Niijima T., Kotake T. et al. Effect of prophylactic treatment with intravesical Epirubicin on recurrence of superficial bladder cancer – the 6th trial of the Japanese Urological Cancer Research Group (JUCRC): a randomized trial of intravesical Epirubicin at dose of 20 mg/4- ml. 30 mg/40 ml. 40 mg/40ml. Eur Urol 2019; 45: 600-5. 26. Au J L.-S., Badalament R.A., Wientjes G. et al. Methods to improve efficacy of intravesical Mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2019; 93(8): 597-604. 27. Van der Heijden A.G., Kiemeney L.A., Gofrit O.N. et al. Preliminary European results of local Microwave Hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2019; 46(1): 65-72. 28. Paroni R., Salonia A., Lev A. et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Clin Pharmacol 2019; 52: 273-8. 29. Malmstrom P.-U. Intravesical therapy of superficial bladder cancer. Clin Rev Oncol Hematol 2017; 47: 109-26.